Hepion Pharmaceuticals Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Hepion Pharmaceuticals.

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for Hepion Pharmaceuticals.

Recommendation Trends

Rating	Oct '23	Nov '23
Strong Buy	0	0
Buy	1	1
Hold	0	0
Sell	0	0
Strong Sell	0	0
Total	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Kumaraguru Raja Brookline Capital	Brookline Capital	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Dec 7, 2023
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy Initiates $3,500	Buy	Initiates	$3,500	+1,217,291.30%	Feb 28, 2022

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-5.30

from -107.35

EPS Next Year

n/a

from -5.30

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-	-465.52	-594.75	-616.07	-107.35	-5.30	-
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	4	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2025
High	-5.46
Avg	-5.30
Low	-5.10

EPS Growth

EPS Growth	2025
High	-
Avg	-
Low	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.